| Detected | Trial | Change |
|---|---|---|
| 2026-05-16 | NCT06717347 A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus… |
Trial sites expanded: 253 -> 256 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-08 | NCT07634471 A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) | Phase 2/3 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06717347 | A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus… | Diffuse Large B-Cell Lymphoma | Recruiting |
| Phase 2/3 | |||
| NCT07634471 | A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) | Follicular Lymphoma | Not Yet Recruiting |
| Phase 2 | |||
| NCT06890884 | A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide… | Lymphoma, Large B-Cell, Diffuse | Recruiting |